Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

NCT00471510 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Androgenetic Alopecia

Interventions

DRUG: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

Sponsor

Neosil, Inc.